Considering its high rate of overexpression in MM and suspected function in tumor progression, we have developed a humanized an anti-CD26 antibody, designated YS110, as a targeted therapy against CD26-positive malignancies, including MM. Here, DPP4 is linked to Miyoshi myopathy.